All PlansCoverageMedium impact
Percutaneous Angioplasty and Stenting of Veins
Regence BlueShield·Vascular Surgery, Cardiology, Nephrology +1 more·Medical Policy
Effective date
Mar 1, 2026
We identified it
Jun 16, 2026
Summary
New medical policy SUR109 establishes coverage criteria for percutaneous angioplasty and stenting of veins, effective March 1, 2026. The policy defines 11 specific medically necessary indications (including dialysis access, vena cava syndrome, May-Thurner syndrome) while considering other venous procedures investigational.
Action Required
Before March 1, 2026: Billing team must review all venous angioplasty and stenting procedures to ensure they meet one of the 11 medically necessary criteria listed in policy SUR109. Update prior authorization processes to verify appropriate indications. Providers must document symptoms, associated diagnoses, and treatments for all cases. Claims for non-covered indications (deep vein thrombosis, chronic cerebrospinal venous insufficiency, venous sinus obstruction) will be denied as investigational.